Kornimate/medical-research-clean huggingface dataset:
efficacy of intra-articular hyaluronate injection for adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: objective: to evaluate the efficacy of intra-articular hyaluronic acid (ha) injections for the treatment of adhesive capsulitis (ac) of the shoulder. design: prospective, case- controlled trial. setting: rehabilitation department of a medical center hospital. participants: patients (30) with ac interventions: the patients received intra-articular glenohumeral joint injections of ha, 60mg, once per week for 3 consecutive weeks. main outcome measures: active and passive range of motion (rom) of the affected shoulder; shoulder pain and disability were measured using 2 questionnaires: the spadi. the patients were evaluated before treatment and were reevaluated 4, 6, 8, 12 weeks after the beginning of the treatment.


Eligibility criteria:
inclusion criteria: a. patients diagnosed with frozen shoulder by a clinical physician based on the patient's medical history, physical examination, x-ray, and ultrasound or magnetic resonance imaging reports. b. clinical course: patients must have a pain score of less than 3, no nighttime shoulder pain, and be in the post-freezing stage, primarily presenting restricted shoulder joint range of motion. c. the affected shoulder joint must have at least two angles of shoulder joint movement reduced by at least 30% compared to the healthy side: shoulder flexion, abduction, and external rotation, or a single affected side abduction angle reduced by 50% relative to the healthy side. d. age between 40 to 70 years old. - exclusion criteria: a. full-thickness tear or massive tear of the rotator cuff tendons or calcific tendinitis. b. presence of systemic rheumatic disease. c. history of shoulder fracture or previous shoulder surgery. d. received shoulder injections for treatment within the last 3 months. e. acute cervical nerve root compression. f. current pregnancy or lactation. g. patients with shoulder instability or cancer. h. patients with cognitive impairment, unable to follow simple instructions, or unable to comply with the study procedures.

Keywords: frozen shoulder hyaluronic acid
perci- medium cut off (mco)

Conditions: Chronic Kidney Failure; Chronic Inflammation

Summary: the medium cut-off dialysis membrane has been developed to provide a significantly extended molecular cut-off compared to conventional high-flux membranes. the medium cut-off membrane allows for a high permeability of molecules up to a molecular weight of 45 kda and has a still limited permeability for albumin (68 kda). the main goal of this project is the evaluation of the new, highly porous and selective dialysis membrane (mco-ci 400) for the treatment of patients with end-stage renal disease in hemodialysis mode and to study its potential to improve chronic inflammation.


Eligibility criteria:
inclusion criteria: * ckd5 ( gfr \< 15ml/min/ 1.73m2) * dialysis treatment for ≥ 3 months * dialysis 3x weekly * vascular access by fistula or cvc * age \> 18 and \< 99 years * ability to give written informed consent exclusion criteria: * missing informed consent form * current clinically manifested infection or within the last two weeks * current crp-value \> 50mg/l or within the last two weeks * intake of any medication applied for immunosuppressive purposes * pregnancy or lactation * participation in a different interventional study

Keywords: ckd5, dialysis, high porous membranes
characterization of eyes with diabetic macular edema that show different treatment response to intravitreal anti-vegf (chartres)

Conditions: Diabetic Macular Edema

Summary: the purpose of this study is to identify diabetic macular edema (dme) characteristics in eyes that show different response to treatment with anti-vegf (vascular endothelial growth factor) injections of lucentis.


Eligibility criteria:
inclusion criteria: * patients with 40 years of age or older. * type 2 diabetes mellitus. * glycosylated hemoglobin (hba1c) ≤ 12% at screening visit. * presence of clinically significant dme involving the center (fovea) diagnosed in at least one eye that is eligible for anti-vegf treatment in the opinion of the investigator. if both eyes are eligible, the one with the worse visual acuity, as assessed at screening visit, will be selected as the study eye. * visual impairment due to dme with bcva ≥ 39 letters and ≤ 73 letters (≥ 20/160 and ≤ 20/40). * central subfield thickness ≥ 300µm. exclusion criteria: * presence of any other ocular disease than dme in the study eye that may confound study results, such as proliferative retinopathy. * previous treatment with vitrectomy or intravitreous injections of triancinolone or anti-vegf drugs in the study eye. * any previous laser photocoagulation (panretinal or focal) in the study eye within 6 months prior to inclusion in this study. * active intraocular inflammation (grade trace or above) in either eye at screening visit. * any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at screening visit. * important refractive errors (myopia \> 6d) or opacification of clear media that interferes with images evaluation. * patients with renal failure or other systemic conditions which, in the opinion of the investigator, would preclude schedule study visits, completion of the study or a safe administration of study medication. * other criteria that in the opinion of the investigator should condition the evaluation purposed.

Keywords: diabetic macular edema anti-vegf treatment response
lipids, inflammation, and cv risk in ra

Conditions: Rheumatoid Arthritis; Cardiovascular Disease

Summary: the objective of this study is to elucidate the relationship between inflammation and lipoprotein atherogenicity, and to determine the relative contribution of inflammation and lipids to cv risk in ra. the central hypothesis of this study is that inflammation and lipoprotein atherogenicity is tightly linked such that both factors are important to assess cv risk in ra. further, the investigators hypothesize that this relationship is obscured by a consideration of routine lipids alone.


Eligibility criteria:
inclusion criteria: * ra diagnosed by a rheumatologist * fulfills the 2010 american college of rheumatology (acr)/european league against rheumatism (eular) criteria for ra * age\>35 * active ra as defined by treating rheumatologist * biologic dmard naive exclusion criteria: * patients on statin or pcsk9 inhibitor therapy * corticosteroid therapy \>10mg prednisone or its equivalent as a maintenance treatment * pregnancy * unstable angina (chest pain) or shortness of breath * severe valvular heart disease * myocarditis * pericarditis * asthma with active wheezing * history of lymphoproliferative disease or melanoma (stage two or higher), active malignancy, or cancer treatment in the last 5 years * active infectious disease (hiv, tuberculosis, or hepatitis b/c)
the acute effects of an isometric loading intervention on lower extremity landing biomechanics in individuals with patellar tendinopathy

Conditions: Tendinopathy

Summary: the purpose of this study is to determine differences in lower extremity landing biomechanics and real-world physical activity between individuals with patellar tendinopathy compared to individuals without patellar tendinopathy,and to determine the acute effects of an isometric loading intervention on lower extremity landing biomechanics in individuals with patellar tendinopathy.


Eligibility criteria:
inclusion criteria: the investigators will recruit a convenience sample of participants who meet the following overall criteria: 1. age 15 and post-pubertal (confirmed by pubertal development scale questionnaire) - 28 years 2. actively participating within an organized sport setting (high school, collegiate, club, competitive intramural sports) in their respective team's weekly training and competitions, quantified by a tegner activity level scale of at least 5. exclusion criteria: the following exclusion criteria will be applied to all participants: 1. any anterior knee pain with no patellar tendon abnormality on ultrasound assessment. 2. history of any knee joint surgery ever. 3. history of other (non-knee) lower extremity surgery in the last 1 year. 4. history of lower extremity injury in last 6 months (other than patellar tendinopathy). 5. an injection (corticosteroids, plasma-rich-protein, etc.) to the patellar tendon in the last 3 months. 6. known history of osteoarthritis or current symptoms related to osteoarthritis (i.e. stiffness, swelling). 7. participation in formal rehabilitation for patellar tendinopathy in prior 3 months 8. known neurological disorders, including: stroke, multiple sclerosis, als, diabetic neuropathy, epilepsy, traumatic brain injury resulting in loss of consciousness, concussion within the last 6 months, cranial neural surgery, balance disorders. 9. use of pacemaker or another implantable electronic device. 10. history of cardiac arrhythmia or any cardiac condition. 11. history of psychiatric disorder. \* 12. history of cancer in the brain or thigh musculature. 13. pubertal development scale score \< 12 (stages 1-4) * note: rationale for exclusion of individuals with a history of psychiatric disorders is that these individuals may have taken or be taking pharmacological agents that could affect pain or neuromuscular control.

Keywords: exercise physical activity biomechanics
ai-based social software to manage warfarin therapy

Conditions: Anticoagulant-induced Bleeding; Warfarin Sodium Causing Adverse Effects in Therapeutic Use

Summary: the investigators have demonstrated that social software could improve warfarin therapy quality by human management. however,the efficiency of management will decline if patients' number expands huge. so it is needed that a human-like and automatic management tool could replace the human work. the aim of this study is to evaluate whether an ai-based social software management model could replace human to guide warfarin therapy.

1. the investigators have developed an ai-based miniprogram, and embedded in the wechat social application. 2. the investigators invited patients receiving warfarin therapy to participant this randomized controlled trial . 3. participants were randomized to the experimental group and control group in a ratio of 1:1. 4. participants' warfarin therapy were managed by an ai-based social miniprogram and a human-based social miniprogram respectively. 5. international normalized ratio(inr) was monitored once a month at least, and the time in therapeutic range was calculated to evaluate the warfarin anticoagulation quality. 6. participants were followed-up for 24 months, and clinical events, including major bleedings and thrombotic events were recorded during follow-up.

Eligibility criteria:
inclusion criteria: * patients with atrial fibrillation * patients with mechanical valve replacement * patients receiving warfarin therapy exclusion criteria: * plan to stop warfarin therapy within 1 years * bleeding within 3 months * refuse to participate in this study * other conditions that the physician considers inappropriate for participation

Keywords: artificial intelligence social software warfarin anticoagulation therapy inr
prevention of hypoglycaemia with predictive insulin suspend using sensor augmented insulin pump in children

Conditions: Type 1 Diabetes Mellitus

Summary: the aim of the study is to prove whether the use of the smartguard feature of the minimed system significantly reduces hypoglycemic excursions and thus provide proactive protection to the user.

this is randomized two-arm parallel controlled open label study that will be conducted at two sites, in slovenia and israel. it is an investigator initiated pediatric clinical study. study will be conducted on pediatric population during two weeks, following a 3 day run-in period that will allow the patients to get familiar with study device and cgm (smartguard off). patients will be asked to continuously wear the study device for 14 days, which will be set up by study staff according to randomization in the specific group. they will be provided with a diary for entering their daily activity, food consumption (carb count) and eventual adverse events.

Eligibility criteria:
inclusion criteria: * informed consent signed by a parent/legal guardian and informed assent signed by the study participant prior study entry * diagnosed with type 1 dm at least 12 months prior to signature of patient informed consent (pic). * age between 8-18 years old (inclusive) at signature of pic * treated by csii with or without cgm at least 3 months prior to signature of pic, but no use of lgs for last two weeks prior to signature of pic. * hba1c value at screening visit ≤10% * knowledgeable on the use of csii, administering treatment, adjusting insulin according to diet and exercise * performance of an average of four (4) smbg per day, as evidenced from patient files, or latest insulin pump or glucose meter download * treated by the investigator's centre for at least 6 months prior signature of pic. * willing to undergo all study procedures exclusion criteria: * hearing or vision impairment so that glucose display and alarms cannot be recognized. * alcohol or drug abuse. * non-compliance with diabetes self-monitoring and disease management * documented cutaneous allergy or disease (allergy to sensor or components of the sensor, psoriasis, staphylococcus, exanthema etc.). * any documented concomitant chronic disease known to affect diabetes control (e.g. altered renal function, active cancer undergoing treatment, crohn's disease, ulcerative colitis, mb addison disease) or any concomitant pharmacological treatment that might modify glycemic values (e.g. chronic corticosteroid therapy), * eating disorders and morbid obesity (defined as adults: bmi\>35 and children bmi \> 2 sd for age) as assessed by the investigator. * any other medical, social or psychological condition that, in the investigator's opinion, makes the patient unable to comply with the study protocol and all study procedures. * patient that does not have a reliable support person. * participation in another clinical study, on-going or completed less than 2 months prior to signature of pic. * pregnancy (per investigator judgment, including pregnancy test if necessary)
"impact of the third molars in oral health-related quality of life"

Conditions: Health-related Quality of Life; Third Molar

Summary: the aim of this study is to evaluate the impact of the third molars in oral health-related quality of life, before and after surgical removal using a validated and frequently used in international investigations instrument (ohip-14).

this is a prospective study that evaluates the oral health-related quality of life through the application of the self-administered ohip-14 before and after the surgical removal of third molars. the inclusion criteria were adults' patients older than 18 years, referred for oral surgery. patients with chronic diseases and acute pericoronitis were excluded. the assessment was performed at three times: pre-surgical planning 1 day before surgery (t0), 10 days (t1) and 2 - 3 months after surgery (t2)

Eligibility criteria:
inclusion criteria: * adults patients over 18 years old exclusion criteria: * patients with chronic diseases and acute pericoronitis

Keywords: health-related quality of life third molar
real-life follow-up of cystic fibrosis patients treated with ivacaftor+lumacaftor (orkambi*)

Conditions: Cystic Fibrosis

Summary: the purpose of the study is to examine the real-life safety and effectiveness of the novel combination ivacaftor+lumacaftor in eligible patients with cystic fibrosis (cf). all patients with cf were eligible if they were 12 years and older, started ivacaftor+lumacaftor outside of a clinical trial between december 15th 2017 and december 15th 2018 in an accredited cf center in france. patient followed-up is based on standardized recommendation of the french cystic fibrosis society. each patient is followed 1 year.

each patient is followed one year with visits at months 1, 3, 6 and 12. at each visit, the following data are recorded: * treatment discontinuation or not. if the treatment was discontinued, reasons for discontinuation * adverse effects * lung function (spirometry) * body mass index * pulmonary exacerbations (intravenous antibiotics) * sputum microbiology * liver enzymes are measured at each visit at the initial and 12 visits, a yearly cf examination is proposed to the patients: * blood tests * chest ct scans * body plethysmography

Eligibility criteria:
inclusion criteria: * patient aged 12 years or older. * patient with cystic fibrosis with presence of two mutations df508 in the cftr gene * patient treated with ivacaftor+lumacaftor (orkambi) exclusion criteria: * refusal to participate in the study * start of orkambi as part of a clinical trial

Keywords: cystic fibrosis ivacaftor lumacaftor
a study of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor mutations

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this single arm, open-label study will evaluate the efficacy and safety of erlotinib (tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) mutations.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic nsclc with egfr mutations * measurable disease according to recist criteria * adequate hematological, renal and liver function exclusion criteria: * previous chemotherapy or therapy against egfr for metastatic disease * symptomatic cerebral metastases * pre-existing disease of the lung parenchyma such as lung fibrosis, lymphangitic carcinomatosis * history of another malignancy except for carcinoma in-situ of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis * concomitant use of coumarins
motivating individuals with lupus to exercise

Conditions: Systemic Lupus Erythematosus

Summary: physical activity and exercise are helpful for managing symptoms like fatigue in people living with systemic lupus erythematosus (lupus; sle). despite research supporting physical activity participation, people with lupus are often inactive and report being afraid to exercise. to that end, this project is a pilot randomized controlled trial for examining the efficacy of a home-based behavioral intervention based on social cognitive theory and motivational interviewing for increasing physical activity and decreasing fatigue.


Eligibility criteria:
inclusion criteria: * diagnosis of lupus * be able to speak and read english * being non-active defined as not engaging in regular activity (150 minutes or more of moderate physical activity per week) * being impacted by fatigue defined as a score of 36 or higher on the fatigue severity scale exclusion criteria: * moderate or high risk for undertaking physical activity
comparison of deviation types among astigmatic children with or without amblyopia

Conditions: Astigmatism of Both Eyes; Amblyopia; Strabismus

Summary: the records of astigmatic children were reviewed and any deviation was investigated at near and distance. refractive errors, stereopsis, convergence insufficiency were also evaluated. children were divided into two groups according to the presence of amblyopia and ocular deviations and other parameters were compared between groups.

the aim of the study was to evaluate deviations in children with ≥1,75 diopter (d) astigmatism with or without amblyopia. the records of children with ≥1,75 d astigmatism were investigated. subjects with and without amblyopia composed group 1 and 2, respectively. the mean age, gender, amount and type of deviation, presence of convergence insufficiency (ci), stereopsis, time of initial spectacle use and follow-up time, differences in best corrected visual acuity (vod) and spherical equivalent (se) between eyes were noted and compared between the groups. best corrected visual acuity (bcva), mean se, astigmatism measurements were also noted and compared between amblyopic, fellow and non-amblyopic eyes.

Eligibility criteria:
inclusion criteria: * astigmatisma ≥1,75 diopter exclusion criteria: * systemic diseases additional ocular diseases neurological diseases
camrelizumab plus apatinib and temozolomide as neoadjuvant in high risk acral melanoma

Conditions: Melanoma; Acral Melanoma; Temozolomide; Apatinib; Camrelizumab; Neoadjuvant; Pathological Response

Summary: neoadjuvant therapy is feasible in stage ⅱ-ⅲ melanoma, carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

patients with resectable melanoma can benefit from neoadjuvant therapy, including improved surgical outcomes, precise management of patients based on neoadjuvant response, and analysis of resistance mechanisms through histological sections for subsequent treatment. at present, there have been a number of clinical trials exploring the effect of neoadjuvant regimens for melanoma, and some published results have shown that neoadjuvant therapy can lead to a higher pathological response rate, thereby improving the rfs of patients. in the past, this site has carried out a clinical study of camrelizumab combined with apatinib and temozolomide for first-line treatment of unresectable acral melanoma, with a high preliminary clinical response rate and safety. based on this, this study intends to evaluate the neoadjuvant treatment of completely resectable melanoma with camrelizumab combined with apatinib and temozolomide in patients with stage iii and iib, iic high-risk melanoma. to comprehensively evaluate the short-term and long-term benefits of neoadjuvant therapy and provide an important reference for neoadjuvant treatment strategies in the acral melanoma population.

Eligibility criteria:
inclusion criteria: 1. age:18-75 years, male or female. 2. histopathologically confirmed acral melanoma (stage ⅱ/ⅲ). 3. has not received any systematic anti-tumor drug treatment. 4. measurable disease based on response evaluation criteria in solid tumors (recist) 1.1. 5. ecog 0-1. 6. adequate organ function. 7. life expectancy of greater than 12 weeks. 8. patient has given written informed consent. exclusion criteria: 1. patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy. 2. known history of hypersensitivity to any component of apatinib, temozolomide, camrelizumab. 3. subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ); 4. subjects with any active autoimmune disease or history of autoimmune disease 5. patients with any unstable systemic disease, including but not limited to: serious infection, uncontrolled diabetes, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, myocardial infarction, congestive heart failure, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease; 6. received a live vaccine within 4 weeks of the first dose of study medication. 7. pregnancy or breast feeding. 8. decision of unsuitableness by principal investigator or physician-in charge.

Keywords: acral melanoma immune checkpoint inhibitors protein kinase inhibitors antineoplastic agents, alkylating